new drug development
Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
vishnu priya
Active In SP
**

Posts: 1
Joined: Jul 2010
#1
28-07-2010, 11:59 AM


my name is vishnu iwant a detail description about new drug develpoment to give a seminar and presentation in the college and i also want a detail notes on parentral drug delivery system
Reply
premeet01245
Active In SP
**

Posts: 4
Joined: Jul 2010
#2
14-08-2010, 04:23 PM

just search on this forum.
Reply
humm
Active In SP
**

Posts: 1
Joined: Jan 2011
#3
26-01-2011, 10:56 AM

wanna some info abt new drug development
Reply
seminar surveyer
Active In SP
**

Posts: 3,541
Joined: Sep 2010
#4
27-01-2011, 11:02 AM



Christopher P. Adams & Van V. Brantner
Bureau of Economics
Federal Trade Commission


Abstract
This paper analyses a detailed data set on drugs in human clinical trials around the world between 1989 and2002. The data provides information on the probabilities with which drugs successfully complete thedifferent phases of the trials and the durations of successful completions. The paper shows that successrates and durations can vary substantially across observable characteristics of the drugs, including primaryindication, originating company, route of administration and chemistry. It suggests that analysis of this typeof data can help us to answer questions such as: Do AIDS drugs get to market faster? Do Biotech drugshave higher probabilities of getting to market? This paper provides some general statistics for analyzing thesequestions.

Introduction
The dynamics of drug development is one of the defining characteristics of the pharmaceutical industry. Despite its importance to the industry, there is little information on how long it takes for particular drugs togo through human clinical trials and the probabilities of successful completion. Recently, a number of authorshave started making use of historical data on the development of drugs through human clinical trials in theUS and elsewhere in the world (for example, Abrantes-Metz, 2003, Kyle, 2002, Danzon et al, 2003). These authors are using this data examine determine the relationship between drug characteristics andsuccessful durations, market entry, and the use of licensing arrangements, respectively. This type ofhistorical data has the potential to provide industry analysts with a much clearer picture of late stagepharmaceutical development and new drug entry. The current paper presents some summary statistics onduration and frequencies of successful completion of the human clinical trials. While this analysis is notsophisticated or detailed enough to provide answers to many of the questions researchers and practitionersare interested in, it does provided readers with some stylized facts to guide future work.The paper analyzes a sample of drugs that have entered human clinical trials somewhere in the worldbetween 1989 and 2002. The data provides information on entry and exit dates from the three differentstages of the human clinical trials for the first indication that the drug was being developed (post-1989). Thedata also provides information on drug characteristics such as primary indication, chemical composition,route of administration and originating company. The analysis provides frequencies with which drugs withdifferent characteristics successfully complete the different stages of the human clinical trials. For example,drugs that have been originally developed by one of the 10 largest drug companies have a higher thanaverage probability of getting to market. The analysis also provides mean durations for drugs thatsuccessfully complete the different stages of the human clinical trials. For example, AIDS drugs are inhuman clinical trials for an average of 5 years, which is 3 years shorter than the average drug in the sample. In general, the results presented should not be interpreted as causal effects of drug characteristics onsuccess rates or successful durations. Rather these results should be interpreted as central tendencies orsimply as statistical observations of the drug development process.


More



Reply

Important Note..!

If you are not satisfied with above reply ,..Please

ASK HERE

So that we will collect data for you and will made reply to the request....OR try below "QUICK REPLY" box to add a reply to this page

Quick Reply
Message
Type your reply to this message here.


Image Verification
Please enter the text contained within the image into the text box below it. This process is used to prevent automated spam bots.
Image Verification
(case insensitive)

Possibly Related Threads...
Thread Author Replies Views Last Post
  TARGETED DRUG DELIVERY SYSTEM PPT study tips 2 1,195 21-05-2014, 09:55 AM
Last Post: seminar project topic
  Drug interaction Report seminar projects maker 0 455 24-09-2013, 02:08 PM
Last Post: seminar projects maker
  USE OF NATURAL PLANT BASED EXCIPIENT AS A BINDER IN THE FORMULATION DEVELOPMENT study tips 1 725 26-07-2013, 01:20 PM
Last Post: livon
  OCULAR DRUG DELIVERY PPT study tips 0 556 01-06-2013, 03:19 PM
Last Post: study tips
  Controlled Drug Delivery System seminar girl 1 1,061 10-12-2012, 12:13 PM
Last Post: seminar tips
  SELF EMULSIFYING DRUG DELIVERY SYSTEMS (SEDDS) AS A NOVEL CONCEPT IN DRUG DELIVERY project girl 0 1,027 06-12-2012, 06:28 PM
Last Post: project girl
  TRANSDERMAL PATCHES: A SYNERGISTIC APPROACH OF DRUG DELIVERY FOR NSAIDs pdf project girl 0 632 01-12-2012, 01:20 PM
Last Post: project girl
  OCULAR DRUG DELIVERY SYSTEM PPT project girl 0 1,202 21-11-2012, 01:54 PM
Last Post: project girl
  Vaginal Drug Delivery System PPT project girl 0 786 16-11-2012, 10:42 AM
Last Post: project girl
  TRANSDERMAL DRUG DELIVERY SYSTEM REPORT project girl 0 603 06-11-2012, 11:49 AM
Last Post: project girl